-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ET-02 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ET-02 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ET-02 in B-Cell Non-Hodgkin Lymphoma Drug Details: ET-02 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Follicular Lymphoma Drug Details: SH-748 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SH-748 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-748 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SH-748 in Marginal Zone B-cell Lymphoma Drug Details: SH-748 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Patritumab Deruxtecan in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Patritumab Deruxtecan in Metastatic Breast Cancer Drug Details: Patritumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Patritumab Deruxtecan in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Patritumab Deruxtecan in Non-Small Cell Lung Cancer Drug...
-
Company Insights
Innovation and Patenting activity of u-blox Holding AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of u-blox Holding AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...